Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer.
about
Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study.Change in non-small-cell lung cancer tumor size in patients treated with nintedanib plus docetaxel: analyses from the Phase III LUME-Lung 1 study
P2860
Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Time since start of first-line ...... ed non-small cell lung cancer.
@en
Time since start of first-line ...... ed non-small cell lung cancer.
@nl
type
label
Time since start of first-line ...... ed non-small cell lung cancer.
@en
Time since start of first-line ...... ed non-small cell lung cancer.
@nl
prefLabel
Time since start of first-line ...... ed non-small cell lung cancer.
@en
Time since start of first-line ...... ed non-small cell lung cancer.
@nl
P2093
P2860
P1433
P1476
Time since start of first-line ...... ed non-small cell lung cancer.
@en
P2093
Anders Mellemgaard
Birgit Gaschler-Markefski
Claudia-Nanette Gann
José Barrueco
Martin Reck
Maya Gottfried
Nasser H Hanna
Patricia Sikken
Rolf Kaiser
Silvia Novello
P2860
P304
P356
10.1136/ESMOOPEN-2016-000102
P577
2017-04-11T00:00:00Z